A Phase 4 interventional study of Optive in Dry Eye Syndromes, sponsored by Innovative Medical. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-04-17.
Sponsored by Innovative Medical · Phase 4, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing carboxymethylcellulose in Dry Eye Syndromes — 2 open to participants now, 2 under way, none of them phase 3. carboxymethylcellulose · Dry Eye Syndromes.
Among the 12 studies testing carboxymethylcellulose in Dry Eye Syndromes, this one is the 4th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2007, is one of 11 in phase 4, and was the 4th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →2 of the 12 studies testing carboxymethylcellulose in Dry Eye Syndromes are open now, in 2 countries. Recruiting first, the newest first:
Andover Research Eye Institute · Sites in United States
Ages 18+
Pokhara Academy of Health Sciences, Western Regional Hospital · Sites in Nepal
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 92 is above the median of 60 across 1,131 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 80 across the 11 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 12 have an industry lead sponsor. The 7 most frequent:
Innovative Medical is the lead sponsor of 51 studies on the registry; none are open to participants now.
15 studies in Dry Eye Syndromes by Innovative Medical: none open now, none under way, none of them phase 3. Of 13 finished, 0 (0%) have results posted.
Among the 15 studies in Dry Eye Syndromes by Innovative Medical, this one is the 3rd largest by enrollment of the 10 interventional ones that give a count, is one of 4 that started in 2007, is one of 14 in phase 4, and was the 7th registered.
Innovative Medical’s Dry Eye Syndromes studies by the year they started, since 2006.
1 of the studies testing carboxymethylcellulose in Dry Eye Syndromes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07635849Pokhara Academy of Health Sciences, Western Regional HospitalRandomized Clinical Trial of Artificial Tears With and Without Preservatives in Patients With Dry Eye Disease | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing carboxymethylcellulose in Dry Eye Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Innovative Medical’s 15 in Dry Eye Syndromes:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess the compatibility of Optive with refractive surgery (PRK and LASIK) post-operatively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Use of systemic medications with ocular drying sequelae:
Drug: Optive
Drug pages: Carboxymethylcellulose · Glycerol
Optive 30ml- (in the eye) Instill one in each eye twice daily starting one week after surgery
Assess compatibility
Time frame: 8 months
comfort
Time frame: 8 months
The record gives a start of May 2007, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Carboxymethylcellulose · Glycerol